Niche Pharmaceutical Plant in New Zealand

An agreement between Fonterra subsidiary, Lactose New Zealand, and GlaxoSmithKline (GSK) will see New Zealand supply the world's largest user of inhalation grade pharmaceutical lactose with half of its total yearly requirements. Under the terms of the agreement announced at the opening of a new $25 million (US$18.5m) plant at Kapuni, Lactose New Zealand will also become GSK's preferred supplier of tablet-grade pharmaceutical lactose.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=0c3d0cef694a76f2&cat=6dcd932030878143)